C-nitroso-derived nitroxyl donors
AssigneeWake Forest University Health Sciences
InventorS. Bruce King
Life of this patent
Estimating the term…
Abstract
Active compounds of Formula (I) are described: wherein: R1 and R2 are each independently C1-C4 alkyl; or R1 and R2 together form a C2-C7 alkylene chain; and Z is a non-steroidal anti-inflammatory drug (NSAID); along with pharmaceutically acceptable salts and prodrug thereof, and methods of using the same.
Claims17
A compound of Formula I:
- wherein:
- R1 and R2 are each independently C1-C4 alkyl;
- or R1 and R2 together form a C2-C7 alkylene chain;
- and
- Z is a non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of aspirin, indomethacin, ibuprofen, fenoprofen, sulindac, naproxen, tolmetin, mefanamic acid, mefclofenamic acid, or a pharmaceutically acceptable salt or prodrug thereof.
A composition comprising a compound of Formula I in a pharmaceutically acceptable carrier:
- wherein:
- R1 and R2 are each independently C1-C4 alkyl;
- or R1 and R2 together form a C2-C7 alkylene chain;
- and
- Z is a non-steroidal anti-inflammatory drug (NSAID);
- or a pharmaceutically acceptable salt thereof.
A method of treating a cardiovascular disorder in a subject in need thereof, comprising administering said subject a treatment-effective amount of a compound of Formula I:
- wherein:
- R1 and R2 are each independently C1-C4 alkyl;
- or R1 and R2 together form a C2-C7 alkylene chain;
- and
- Z is a non-steroidal anti-inflammatory drug (NSAID);
- or a pharmaceutically acceptable salt thereof.
A method of treating gastrointestinal side effects associated with NSAID treatment in a subject in need thereof, comprising administering said subject a treatment-effective amount of a compound of Formula I:
- wherein:
- R1 and R2 are each independently C1-C4 alkyl;
- or R1 and R2 together form a C2-C7 alkylene chain;
- and
- Z is a non-steroidal anti-inflammatory drug (NSAID);
- or a pharmaceutically acceptable salt or prodrug thereof.
A pharmaceutical composition for treating congestive heart failure, comprising, in combination, a pharmaceutically acceptable carrier and a treatment effective amount of a compound of Formula (III):
- wherein:
- R1 and R2 are each independently C1-C4 alkyl;
- and
- R3 is C1-C5 alkyl, haloalkyl or aryl,
- or a pharmaceutically acceptable salt or prodrug thereof.
A pharmaceutical composition for treating congestive heart failure, comprising, in combination, a pharmaceutically acceptable carrier and a treatment effective amount of a compound selected from the group consisting of
- or a pharmaceutically acceptable salt or prodrug thereof.
A method of treating or congestive heart failure in a subject in need thereof, comprising administering said subject a treatment effective amount of a compound of Formula (III):
- wherein:
- R1 and R2 are each independently C1-C4 alkyl;
- or R1 and R2 together form a C2-C7 alkylene chain;
- and
- R3 is C1-C5 alkyl, haloalkyl or aryl,
- or a pharmaceutically acceptable salt or prodrug thereof.
Dependencies are inferred from the claim text.